EyePoint to Cut 53% of Workforce After Trial Failure
EyePoint said it would stop studies of its experimental age-related vision disease drug after a second late-stage trial failed. Its shares fell more than 75% in premarket trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.